TY - JOUR
T1 - The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2
T2 - The role of JNK signaling
AU - Liao, Siyun
AU - Porter, Darius
AU - Scott, Alana
AU - Newman, Gilbert
AU - Doetschman, Thomas
AU - Schultz, Jo El J.
N1 - Funding Information:
This work was supported by grants from the American Heart Association (SDG 23004N), the Pharmaceutical Research and Manufacturers of America (Research Starter Grant), NIH/NHLBI RO1 (HL075633) to Jo El J. Schultz and NIH/NHLBI R01 (HL070174) to Thomas Doetschman. The authors would like to acknowledge M. Bender, A. Whitaker and S. Pawlowski for their excellent animal husbandry. Also, the authors would like to acknowledge Cephalon, Incorporated (Frazer, PA) for the generous gift of the JNK pathway inhibitor, CEP11004.
PY - 2007/1
Y1 - 2007/1
N2 - Our laboratory showed that overexpression of fibroblast growth factor-2 (FGF2) protected the heart against ischemia-reperfusion injury. FGF2 has different protein isoforms (low [LMW] and high [HMW] molecular weight isoforms) produced from alternative translation start sites. However, which FGF2 isoform(s) mediates this cardioprotection, and which signaling pathway (i.e., mitogen-activated protein kinase (MAPK)) elicits FGF2 isoform-induced cardioprotection remains to be elucidated. Methods and results: Wildtype, Fgf2 KO (absence of all FGF2 isoforms) and FGF2 LMWKO (absence of LMW isoform) hearts were subjected to an ex vivo work-performing heart ischemic model of 60 min ischemia and 120 min reperfusion. There was a significant decrease in the recovery of post-ischemic contractile function (p < 0.05) in Fgf2 KO and FGF2 LMWKO mouse hearts compared to wildtype hearts. Following ischemia-reperfusion injury, MKK4/7, JNK, and c-Jun were significantly phosphorylated (i.e., activated), and the levels of TUNEL-positive nuclei and caspase 3 cleavage were significantly increased in vehicle-treated Fgf2 KO and FGF2 LMWKO compared to wildtype hearts (p < 0.05). A novel JNK pathway inhibitor, CEP11004 (50 nM), significantly restored the post-ischemic contractile function and reduced myocardial cell death, as measured by CK release and apoptotic markers, compared to DMSO-treated cohorts (p < 0.05). Overall, our data indicate that the LMW isoform has an important role in restoring cardiac function after ischemia-reperfusion (I/R) injury. These results provide unequivocal evidence that inhibition of JNK signaling is involved in FGF2 LMW isoform-mediated cardioprotection and that the potential mechanism may be through inhibition of the apoptotic process.
AB - Our laboratory showed that overexpression of fibroblast growth factor-2 (FGF2) protected the heart against ischemia-reperfusion injury. FGF2 has different protein isoforms (low [LMW] and high [HMW] molecular weight isoforms) produced from alternative translation start sites. However, which FGF2 isoform(s) mediates this cardioprotection, and which signaling pathway (i.e., mitogen-activated protein kinase (MAPK)) elicits FGF2 isoform-induced cardioprotection remains to be elucidated. Methods and results: Wildtype, Fgf2 KO (absence of all FGF2 isoforms) and FGF2 LMWKO (absence of LMW isoform) hearts were subjected to an ex vivo work-performing heart ischemic model of 60 min ischemia and 120 min reperfusion. There was a significant decrease in the recovery of post-ischemic contractile function (p < 0.05) in Fgf2 KO and FGF2 LMWKO mouse hearts compared to wildtype hearts. Following ischemia-reperfusion injury, MKK4/7, JNK, and c-Jun were significantly phosphorylated (i.e., activated), and the levels of TUNEL-positive nuclei and caspase 3 cleavage were significantly increased in vehicle-treated Fgf2 KO and FGF2 LMWKO compared to wildtype hearts (p < 0.05). A novel JNK pathway inhibitor, CEP11004 (50 nM), significantly restored the post-ischemic contractile function and reduced myocardial cell death, as measured by CK release and apoptotic markers, compared to DMSO-treated cohorts (p < 0.05). Overall, our data indicate that the LMW isoform has an important role in restoring cardiac function after ischemia-reperfusion (I/R) injury. These results provide unequivocal evidence that inhibition of JNK signaling is involved in FGF2 LMW isoform-mediated cardioprotection and that the potential mechanism may be through inhibition of the apoptotic process.
KW - Apoptosis
KW - Cardioprotection
KW - Fibroblast growth factor
KW - Genetically altered mice
KW - Ischemia-reperfusion injury
KW - JNK signaling
KW - Low molecular weight isoform
UR - http://www.scopus.com/inward/record.url?scp=33845657462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845657462&partnerID=8YFLogxK
U2 - 10.1016/j.yjmcc.2006.10.005
DO - 10.1016/j.yjmcc.2006.10.005
M3 - Article
C2 - 17150229
AN - SCOPUS:33845657462
SN - 0022-2828
VL - 42
SP - 106
EP - 120
JO - Journal of Molecular and Cellular Cardiology
JF - Journal of Molecular and Cellular Cardiology
IS - 1
ER -